Original Investigation | Pacific Coast Surgical Association

Correlation of Breast Cancer Axillary Lymph Node Metastases With Stem Cell Mutations

Cory A. Donovan, MD1; Rodney F. Pommier, MD1; Robynn Schillace, PhD1; Steven O’Neill, BM1; Patrick Muller, BS1; Jennifer L. Alabran, MS1; Juliana E. Hansen, MD2; Jennifer A. Murphy, MD2; Arpana M. Naik, MD1; John T. Vetto, MD1; SuEllen J. Pommier, PhD1
[+] Author Affiliations
1Division of Surgical Oncology, Department of Surgery, Oregon Health & Science University, Portland
2Division of Plastic Surgery, Department of Surgery, Oregon Health & Science University, Portland
JAMA Surg. 2013;148(9):873-878. doi:10.1001/jamasurg.2013.3028.
Text Size: A A A
Published online

Importance  Mutations in oncogenes AKT1, HRAS, and PIK3CA in breast cancers result in abnormal PI3K/Akt signaling and tumor proliferation. They occur in ductal carcinoma in situ, in breast cancers, and in breast cancer stem and progenitor cells (BCSCs).

Objectives  To determine if variability in clinical presentation at diagnosis correlates with PI3K/Akt mutations in BCSCs and provides an early prognostic indicator of increased progression and metastatic potential.

Design, Setting, and Participants  Malignant (BCSCs) and benign stem cells were collected from fresh surgical specimens via cell sorting and tested for oncogene mutations in a university hospital surgical oncology research laboratory from 30 invasive ductal breast cancers (stages IA through IIIB).

Main Outcomes and Measures  Presence of AKT1, HRAS, and PIK3CA mutations in BCSCs and their correlation with tumor mutations, pathologic tumor stage, tumor histologic grade, tumor hormone receptor status, lymph node metastases, and patient age and condition at the last follow-up contact.

Results  Ten tumors had mutations in their BCSCs. In total, 9 tumors with BCSC mutations and 4 tumors with BCSCs without mutations had associated tumor present in the lymph nodes (P = .001).

Conclusions and Relevance  Tumors in which BCSCs have defects in PI3K/Akt signaling are significantly more likely to manifest nodal metastases. These oncogenic defects may be missed by gross molecular testing of the tumor and are markers of more aggressive breast cancer. Molecular profiling of BCSCs may identify patients who would likely benefit from PI3K/Akt inhibitors, which are being tested in clinical trials.

Figures in this Article

Sign In to Access Full Content

Don't have Access?

Register and get free email Table of Contents alerts, saved searches, PowerPoint downloads, CME quizzes, and more

Subscribe for full-text access to content from 1998 forward and a host of useful features

Activate your current subscription (AMA members and current subscribers)

Purchase Online Access to this article for 24 hours


Place holder to copy figure label and caption
Figure 1.
PI3K/Akt Signaling Pathway, With Downstream Results

Extracellular signaling molecules interact with surface g-proteins, resulting in activation of PI3K, which phosphorylates phosphatidylinositol 3,4,5-trisphosphate (PIP3), which in turn activates Akt. Activation of Akt initiates several intracellular processes related to cell survival, protein synthesis, proliferation, and glucose metabolism. PTEN acts as a negative feedback mechanism on PIP3.

Graphic Jump Location
Place holder to copy figure label and caption
Figure 2.
Axillary Lymph Node Metastases and Breast Cancer Stem Cell Mutations

Lymph node metastases are significantly increased in patients having breast cancer stem and progenitor cell (BCSC) mutations compared with patients not having BCSC mutations (P = .001).

Graphic Jump Location




Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Submit a Comment


Some tools below are only available to our subscribers or users with an online account.

Sign In to Access Full Content

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...
Articles Related By Topic
Related Topics
PubMed Articles